Storm-Versloot Marja N, Vos Cornelis G, Ubbink Dirk T, Vermeulen Hester
Department of Surgery, Academic Medical Centre at the University of Amsterdam, Meibergdreef 9, Amsterdam, Netherlands, 1105 AZ.
Cochrane Database Syst Rev. 2010 Mar 17(3):CD006478. doi: 10.1002/14651858.CD006478.pub2.
Silver-containing treatments are popular and used in wound treatments to combat a broad spectrum of pathogens, but evidence of their effectiveness in preventing wound infection or promoting healing is lacking.
To establish the effects of silver-containing wound dressings and topical agents in preventing wound infection and healing of wounds.
We searched the Cochrane Wounds Group Specialised Register (6 May 2009); The Cochrane Central Register of Controlled Trials (CENTRAL) (2009 Issue 2); Ovid MEDLINE (1950 to April Week 4 2009); Ovid EMBASE (1980 to 2009 Week 18); EBSCO CINAHL (1982 to April Week 4 2009) and Digital Dissertations (to May 2009) for relevant trials. We contacted manufacturers and distributors.
Randomised controlled trials (RCTs) comparing silver-containing wound dressings and topical agents with silver-containing and non silver-containing comparators on uninfected wounds.
Two authors independently selected trials, assessed risk of bias, and extracted data.
We identified 26 RCTs (2066 patients). Heterogeneity of treatments and outcomes precluded meta-analysis. We grouped results according to wound type, and silver preparation.BurnsThirteen trials compared topical silver (in a variety of formulations - including silver sulphadiazine (SSD) cream) with non-silver dressings. One trial showed fewer infections with silver nitrate when compared with a non-silver dressing, but three trials showed significantly more infection with SSD than with the non-silver dressing.Six trials compared SSD cream with silver-containing dressings. One showed significantly fewer infections with the silver-containing dressing (Hydron AgSD) compared with SSD, the remaining five found no evidence of a difference.One trial compared two silver-containing dressings, and showed a significantly lower infection rate with silver-coated gauze (Acticoat(R)) than with silver nitrate gauze.Other woundsSix trials compared SSD/silver-containing dressings with non-silver dressings (nine dressings in total). Most comparisons (seven) found no significant differences in infection rates; one trial in a variety of wounds exhibited significantly fewer infections with SSD/hydrocolloid, but another, in acute wounds, found significantly more infections with SSD. Only one comparison showed a significant reduction in healing time associated with a silver-containing hydrofibre dressing in diabetic foot ulcers.
AUTHORS' CONCLUSIONS: There is insufficient evidence to establish whether silver-containing dressings or topical agents promote wound healing or prevent wound infection; some poor quality evidence for SSD suggests the opposite.
含银治疗方法很常见,被用于伤口治疗以对抗多种病原体,但缺乏其预防伤口感染或促进愈合有效性的证据。
确定含银伤口敷料和外用剂在预防伤口感染及促进伤口愈合方面的效果。
我们检索了Cochrane伤口小组专业注册库(2009年5月6日);Cochrane对照试验中心注册库(CENTRAL)(2009年第2期);Ovid MEDLINE(1950年至2009年第4周);Ovid EMBASE(1980年至2009年第18周);EBSCO CINAHL(1982年至2009年第4周)以及学位论文数据库(至2009年5月)以查找相关试验。我们联系了制造商和经销商。
比较含银伤口敷料和外用剂与含银及不含银对照物用于未感染伤口的随机对照试验(RCT)。
两位作者独立选择试验、评估偏倚风险并提取数据。
我们确定了26项RCT(2066例患者)。治疗方法和结果的异质性使得无法进行荟萃分析。我们根据伤口类型和银制剂对结果进行了分组。
烧伤
13项试验比较了局部用银(多种制剂,包括磺胺嘧啶银(SSD)乳膏)与不含银的敷料。一项试验显示硝酸银组感染少于不含银敷料组,但三项试验显示SSD组感染显著多于不含银敷料组。
6项试验比较了SSD乳膏与含银敷料。一项试验显示含银敷料(Hydron AgSD)组感染显著少于SSD组,其余5项未发现差异。
一项试验比较了两种含银敷料,显示镀银纱布(Acticoat®)感染率显著低于硝酸银纱布。
其他伤口
6项试验比较了SSD/含银敷料与不含银敷料(共9种敷料)。大多数比较(7项)发现感染率无显著差异;一项针对多种伤口的试验显示SSD/水胶体组感染显著减少,但另一项针对急性伤口的试验显示SSD组感染显著增加。仅一项比较显示含银水纤维敷料用于糖尿病足溃疡时愈合时间显著缩短。
没有足够证据确定含银敷料或外用剂是否能促进伤口愈合或预防伤口感染;一些关于SSD的低质量证据显示情况相反。